Efficacy and safety of Daclizumab high yield process versus Interferon β 1a in patients with relapsing-remitting multiple sclerosis

Title
Efficacy and safety of Daclizumab high yield process versus Interferon β 1a in patients with relapsing-remitting multiple sclerosis

Type of intervention
Drug

Form of MS
Relapsing-remitting

Brief summary
The existing scientific and clinical experience with DAC HYP supports its further investigation in the management of multiple sclerosis (MS). This study is being conducted to determine the safety and efficacy of DAC HYP compared to IFN β-1a in preventing MS relapse in subjects with relapsing remitting MS (RRMS) when DAC HYP 150mg is administered SC once every 4 weeks for 96 to 144 weeks as compared to a 30mg IM injection of Interferon β1a once weekly for 96 to 144 weeks.

Inclusion criteria

Anticipated start date

Recruitment status
recruiting

Recruitment contacts
decidestudy@biogenidec.com

Further details
http://clinicaltrials.gov/ct2/show/NCT01064401?term=multiple+sclerosis&recr=Open&cntry1=PA%3AAU&rank=4

Region
NSW, QLD, SA, VIC

Trial results

Last updated: May 2011